IR Licensing and Partnerships

The GSK licensing deal is reportedly worth up to $690 million.

The agreement is focused on advancing ATG-201, a bispecific T-cell engager therapy targeting B cell-driven autoimmune diseases.

Teva Pharmaceuticals has secured $400 million from Blackstone Life Sciences to advance duvakitug, an experimental monoclonal antibody in Phase III trials for ulcerative colitis and Crohn's disease.

Boehringer Ingelheim acquires an exclusive license for a preclinical oral immunology program from Sitryx in a deal worth over $500 million in milestones.

Novo Nordisk partners with Vivtex Corporation to develop next-generation oral biologics for obesity and diabetes, while GSK agrees to acquire 35Pharma Inc. to expand its pulmonary hypertension pipeline.

Astellas Pharma Inc. and Vir Biotechnology form a global collaboration to develop VIR-5500, an investigational PSMA-targeted CD3 T-cell engager for prostate cancer.

Hims & Hers has agreed to acquire Australia-based Eucalyptus for up to $1.15 billion, expanding its international footprint across Australia, Canada, Germany and the U.K.

CSL Limited has licensed global development and commercialization rights for clazakizumab to Eli Lilly and Company outside of ESKD-related cardiovascular risk.

THX Pharma’s licensing deal with Biocodex pairs late-stage rare disease assets with commercial infrastructure and non-dilutive funding, highlighting how biotech companies are sharing risk and leveraging partnerships to advance ultra-rare pediatric programs toward market.

Eli Lilly’s deals with Orna Therapeutics and Innovent Biologics helps structure Lilly's global development and commercialization in ways that balance regional expertise with worldwide scale.

The deal highlights how RNAi is moving into a more industrial phase of drug development, as large pharmaceutical companies look to pair advanced delivery technologies with the scale and durability

The collaboration highlights how pharmaceutical companies are pairing capital and global infrastructure with platform technologies that deliver differentiated dosing and durability.

The research collaboration will leverage Seamless’ recombinase technology to develop programmable treatments for hearing loss.

The collaboration with Qilu extends Insilico’s application of generative AI into cardiometabolic disease drug discovery, with both companies aiming to advance candidates from early design through development under a shared strategic framework.

The collaboration agreement strengthens Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.

Mirum Pharmaceuticals’ acquisition of Bluejay Therapeutics adds brelovitug to its pipeline, positioning the company for a potential first approved treatment for chronic hepatitis delta virus while reinforcing its focus on late-stage rare liver disease development.

Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a tumor-activated therapy for solid tumors, combining Janux’s early-stage platform innovation with Bristol Myers Squibb’s clinical and commercial scale.

Novavax and Pfizer announce a non-exclusive licensing deal giving Pfizer access to Novavax’s Matrix-M adjuvant technology, a move that underscores Novavax’s shift toward partnership-driven growth.

Regulatory approval is no longer simply representative of the finish line—but instead can serve as a key launching point to evidence-driven insights that create more timely and broader product access.

Shionogi and GSK are streamlining ViiV Healthcare’s ownership by buying out Pfizer’s 11.7% stake, leaving the HIV specialist jointly owned by its two long-time partners.

GSK is strengthening its allergy and immunology pipeline with a $2.2 billion acquisition of RAPT Therapeutics which includes ozureprubart, a long-acting, potentially best-in-class anti-IgE antibody.

Shanghai Henlius used the 2026 J.P. Morgan Healthcare Conference to announce an exclusive global license for a potentially best-in-class anti-IL-1RAP monoclonal antibody that expands the company beyond oncology into high-unmet-need autoimmune and inflammatory diseases.

Nimbus Therapeutics and Eli Lilly expand partnership with a new multi-year research and licensing collaboration aimed at advancing next-generation oral therapies for obesity and metabolic disease.

AstraZeneca’s exclusive global licensing deal for Jacobio’s pan-KRAS inhibitor JAB-23E73 underscores a renewed industry push of one of oncology’s most elusive targets.

A pair of deal announcements underscore continued strategic reshuffling in biopharma, with Harbour BioMed striking a potentially billion-dollar collaboration with Bristol Myers Squibb to advance next-generation multispecific antibodies, while VYNE Therapeutics agreed to merge with Yarrow Bioscience to create a well-capitalized company focused on developing a first-in-class TSHR antibody for Graves’ disease and thyroid eye disease.